Press release
Fragment-Based Drug Discovery Market Accelerates as Pharma Shifts Toward Faster, More Precise Drug Design
Fragment-Based Drug Discovery Market
Introduction
The global fragment-based drug discovery (FBDD) market is expanding rapidly as pharmaceutical and biotechnology companies increasingly adopt fragment screening and structure-based design tools to accelerate early-stage drug development. FBDD enables researchers to identify low-molecular-weight chemical fragments that bind to disease targets with high efficiency, reducing development timelines and improving success rates in clinical pipelines. With rising demand for precision medicines, improved structural biology tools, and broader use of NMR, X-ray crystallography, and AI/ML-enabled screening platforms, the market is entering a high-growth phase.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72919
Key Takeaways
• Market Size (2023): USD 1.52 billion
• Forecast (2034): USD 5.84 billion
• CAGR (2024-2034): 12.9%
• Growth fueled by expansion of oncology pipelines, AI-enabled drug discovery, and improved hit-to-lead optimization tools.
• North America leads, while Asia Pacific shows fastest growth due to increasing biopharma R&D investments.
Market Story
Fragment-based drug discovery has become one of the most reliable and cost-efficient approaches in modern drug design. Compared with traditional high-throughput screening, FBDD uses smaller libraries of fragments, enabling faster hit identification, clearer binding interactions, and more rational medicinal chemistry optimization.
Pharmaceutical companies are increasingly using FBDD to develop therapies for oncology, infectious diseases, neurological disorders, and rare diseases. Several FDA-approved drugs-including Venetoclax and Vemurafenib-were developed using fragment-based approaches, validating the method and driving wider adoption.
Moreover, the integration of AI, cryo-EM, computational modeling, and machine-assisted fragment optimization has accelerated the shift toward FBDD-driven pipelines. These technologies allow researchers to rapidly design, test, and refine new therapeutic candidates, significantly lowering project risk and costs.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72919/fragment-based-drug-discovery-market
Market Segmentation & Growth Analysis
By Technology
• X-ray Crystallography - Most widely used; provides detailed atomic interactions
• NMR Spectroscopy - Strong for weak binders and fragment screening
• Surface Plasmon Resonance (SPR) - Real-time binding kinetics
• Cryo-Electron Microscopy (Cryo-EM) - Rapidly gaining adoption
• Computational & AI-based Screening - Fastest-growing segment
By Application
• Oncology - Largest and fastest-growing; high unmet therapeutic need
• Infectious Diseases - Essential for antiviral and antibacterial drug design
• Neurological Disorders - Enables targeting complex protein interactions
• Autoimmune & Rare Diseases - Growing use in pathway-specific therapies
By End-User
• Pharmaceutical & Biotechnology Companies - Primary users of FBDD platforms
• Academic & Research Institutes
• Contract Research Organizations (CROs) - Growing outsourcing trend
By Region
• North America: Largest share; strong biotech ecosystem
• Europe: Leading research hubs in U.K., Germany, Switzerland
• Asia Pacific: CAGR 14.8%, fastest growth due to China, India, Japan
• Rest of World: Expanding R&D investments in Brazil, UAE, and South Africa
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72919
Recent Developments
• AI-driven fragment screening platforms launched by major biotech companies
• Increase in Big Pharma-CRO partnerships for outsourced early-stage discovery
• Advancements in cryo-EM improving resolution of complex protein targets
• New fragment libraries designed for covalent inhibitors and RNA-targeting drugs
• Multiple clinical candidates from FBDD entered Phase II and Phase III pipelines
Expert Quote
"Fragment-based drug discovery has moved from a niche method to a mainstream engine of innovation in pharma pipelines. Its speed, precision, and compatibility with AI make it a core driver of next-generation therapeutics."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Drivers & Forecast
Key forces powering market growth include:
• The need for faster and more cost-efficient drug discovery methods
• Rising prevalence of cancer and infectious diseases
• Adoption of computational tools + machine learning for fragment optimization
• Growth of CROs offering integrated FBDD services
• Increasing approvals of FBDD-derived drugs
With a strong 12.9% CAGR, the market will reach USD 5.84 billion by 2034, driven by global R&D investments and expansion of precision medicine therapeutics.
Government Initiatives
• US NIH, EU Horizon, and China's 14th Five-Year Plan are funding structural biology and AI-driven discovery
• Accelerated regulatory pathways for oncology and rare diseases are enabling quicker translation of FBDD pipelines
• National R&D tax incentives supporting biotech expansion in Asia Pacific
Conclusion
The fragment-based drug discovery market is entering a high-growth era, shaped by structural biology breakthroughs, AI-driven screening technologies, and the global push for faster, more precise drug development. With expected revenues of USD 5.84 billion by 2034, FBDD will continue to drive innovation across oncology, genetic diseases, and infectious disease therapeutics.
This report is also available in the following languages : Japanese (フラグメントベースの創薬市場), Korean (후라그먼트베이스의 創薬시장), Chinese (후라그먼트베스의 创薬시장), French (Marché de la découverte de médicaments basée sur les fragments), German (Markt für fragmentbasierte Wirkstoffforschung), and Italian (Mercato della scoperta di farmaci basato sui frammenti), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72919
Our More Reports:
BCMA Targeted Therapies Market
https://exactitudeconsultancy.com/reports/73163/bcma-targeted-therapies-market
Antibacterial Drug Resistance Market
https://exactitudeconsultancy.com/reports/73165/antibacterial-drug-resistance-market
PDE Inhibitors Market
https://exactitudeconsultancy.com/reports/73167/pde-inhibitors-market
HDAC Inhibitors Market
https://exactitudeconsultancy.com/reports/73169/hdac-inhibitors-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fragment-Based Drug Discovery Market Accelerates as Pharma Shifts Toward Faster, More Precise Drug Design here
News-ID: 4300828 • Views: …
More Releases from Exactitude Consultancy
Neoantigen Targeted Therapies Market Trends, Innovations, and Forecast Analysis
Neoantigen targeted therapies are a revolutionary class of immunotherapies that aim to stimulate the body's immune system to recognize and attack cancer cells. Neoantigens are tumor-specific antigens that arise from mutations in the DNA of cancer cells. These mutations produce abnormal proteins that are not present in normal cells, making them ideal targets for immune system recognition. Neoantigen-based therapies focus on developing personalized treatments by targeting these unique antigens, making…
T-Cell Therapy Market Emerging Opportunities and Strategic Insights
T-cell therapy is an innovative form of immunotherapy that involves the use of T-cells, a type of white blood cell, to treat various diseases, primarily cancer. These therapies work by enhancing the body's immune system to target and destroy cancer cells or pathogens. One of the most notable developments in T-cell therapy is CAR-T (Chimeric Antigen Receptor T-cell) therapy, which involves genetically modifying a patient's own T-cells to express receptors…
Abuse Deterrent Formulations Market Drivers, Challenges, and Future Prospects
Abuse deterrent formulations (ADFs) are pharmaceutical products designed to prevent or reduce the potential for misuse, abuse, or accidental overdose. These formulations are primarily applied to opioids and other high-risk medications that can be abused due to their addictive properties. The goal of abuse deterrent technologies is to make it more difficult to misuse medications by tampering, crushing, or altering the form of the drug. As the opioid epidemic continues…
Cell Reprogramming Market Grows Cagr 16.5% from 2024-2034
The global cell reprogramming market is projected to accelerate rapidly as induced pluripotent stem cells (iPSCs), gene-editing tools, and regenerative therapies reshape disease treatment and drug discovery.
Introduction
The cell reprogramming market is undergoing a major growth phase, driven by advancements in regenerative medicine, iPSC technology, and CRISPR-based gene editing platforms. Cell reprogramming enables the transformation of adult somatic cells into different cell types, unlocking unprecedented opportunities for personalized medicine, disease modeling,…
More Releases for FBDD
Fragment-Based Drug Discovery Market to Reach USD 3.2 Billion by 2035, Driven by …
The global Fragment-based Drug Discovery (FBDD) Market is set for robust growth, projected to expand from US$ 1.1 billion in 2024 to US$ 3.2 billion by 2035, registering a strong CAGR of 10.6%, according to the latest market analysis. Increasing adoption of fragment-based techniques in drug design, the emergence of innovative fragment libraries, and expanding applications in oncology and central nervous system (CNS) disorders are key forces propelling the market…
Fragment-Based Drug Discovery Market Size, Share, Growth Forecast 2023-2032
The Fragment-Based Drug Discovery (FBDD) market has been gaining traction in recent years, emerging as a transformative approach in the pharmaceutical and biotechnology industries. The market size for FBDD was valued at USD 1.1 billion in 2022 and is projected to reach USD 3.8 billion by 2032, growing at a remarkable compound annual growth rate (CAGR) of 14.0% from 2023 to 2032. This article delves into the competitive landscape, future…
Fragment Based Drug Discovery Market Set to Reach USD 2.1 billion by 2031, Surgi …
The fragment-based drug discovery market encompasses a wide range of stakeholders, including pharmaceutical companies, contract research organizations (CROs), academic institutions, and technology providers. FBDD offers several advantages over traditional high-throughput screening approaches, including the ability to sample chemical space more comprehensively, target protein-protein interactions, and access novel binding sites that may be challenging to target with larger, more complex molecules. As a result, FBDD has gained traction in the pharmaceutical…
Global Fragment-Based Drug Discovery Market Outlook 2031
𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗿𝗮𝗴𝗺𝗲𝗻𝘁-𝗕𝗮𝘀𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘂𝘁𝗹𝗼𝗼𝗸 𝟮𝟬𝟯𝟭
The global fragment-based drug discovery (FBDD) market is poised for remarkable growth, with a projected compound annual growth rate (CAGR) of 11.5% from 2023 to 2031. This innovative approach to early-stage drug development has gained substantial attention due to its ability to revolutionize the way we discover and develop new therapeutic agents. In 2022, the FBDD market was valued at US$ 795.4 million, and…
Fragment-Based Drug Discovery Market Research Insight 2022| Industry Development …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Fragment-Based Drug Discovery Market by (technique (x-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), service (library screening, fragment screening and fragment optimization), End-users (hospitals, industry players and non-industry players) - Market Outlook and Industry Analysis 2030"
Get Demo Sample copy of Fragment-Based Drug Discovery Market Report at: https://www.insightaceanalytic.com/request-sample/1175
Over the…
Fragment-based Drug Discovery Market Key Trends & Industry Forecast 2015 - 2023
38.4% of the global fragment-based drug discovery market was collectively held by its top three players in 2014. Astex Pharmaceuticals, Charles River Laboratories International, Inc., and Sygnature Discovery were the key contributors to the market revenue at the time and are expected to retain their lead in the near future. A new research report released by Transparency Market Research states that with 52.3% of the global fragment-based drug discovery market…
